ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

14th June, 2021

To,
Listing Compliance Department
Metropolitan Stock Exchange of India Ltd.
Vibgyor Towers, 4th Floor, Plot No. C-62,
G-Block, Opposite Trident Hotel,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400098
Symbol: AFDIL, Series: BE

Dear Sir/Madam ,

Sub: Outcome of Board Meeting held on 14th June, 2021 pursuant to Regulation 30 and Submission of Audited Standalone and Consolidated Financial Results for the Quarter and Financial year ended 31st March, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

We refer to our letter dated 4th June, 2021 informing you of our Board Meeting that is scheduled today. We wish to inform you that the Board of Directors of the Company at its Meeting held on today i.e. 14th June, 2021 at 3.00 p.m. has *interalia* considered and approved the following:

1. The Audited Standalone and Consolidated Financial Results for the quarter and financial year ended 31st March, 2021 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with

- Auditor's Report from Statutory Auditors of the Company for the year ended 31st March, 2021 with unmodified opinion (on Standalone and Consolidated Financial Statements Separately) enclosed as ***Annexure A***

- A declaration by the Director of the Company regarding Audit report with unmodified opinion enclosed as ***Annexure B***

2. Recommendation of Dividend of ₹ 1.50/- /-(Rupees One Rupee Fifty Paisa only) per share on the equity share capital for the year ended 31st March, 2021 subject to approval by Members at ensuing Annual General Meeting of the Company.

3. In terms of Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company has considered and approved the following matters:

ANGLO-FRENCH DRUGS & INDUSTRIES LTD. Bangalore-10

REGD.OFF.: 41,3rd Cross, V Block, Rajajinagar, Bangalore - 560 010
Tel.: 080 - 23154770 Fax : 080 - 23389963, 23306596 E - mail : contact@afdil.com
Corporate Indentity No : L24230KA1923PLC010205 Website : www.afdil.com

a) Change in designation of Mr. Sanatkumar Shirali (DIN:05260386) from Non-Executive Director to Independent Director w.e.f 14th June, 2021 pursuant to recommendation of Nomination and Remuneration Committee of the Company and subject to shareholder's approval.

Mr. Sanat Shirali is not debarred from holding the office of a Director by virtue of any SEBI order or any other authority.

b) Cessation of Directorship of Mr. Shashikant More (DIN: 08397618) as Nominee Director.

c) Appointment of Mrs. Girija Subramanian (DIN: 09196957) as Nominee Director of the Company w.e.f 14th June, 2021, subject to shareholder's approval.

Mrs. Girija Subramanian is not debarred from holding the office of a Director by virtue of any SEBI order or any other authority.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are attached as ***Annexure C***.

d) Appointment of Rao, Murthy & Associates, Cost Accountants (Firm Regn No. 000065) as the Cost Auditors of the Company for the Financial year 2021-22.

e) Appointment of Swaroop Suri & Associates, Practising Company Secretaries (CP No. 9997) as the Secretarial Auditors of the Company for the Financial year 2021-22.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 regarding change in auditors are attached as ***Annexure D***.

f) The 98th Annual General Meeting of the Company will be held on 13th day of August, 2021 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM").

The Meeting of Board of Directors commenced through Video Conferencing at 3.00 p.m. and concluded at 6.20 p.m.

Please take the above information on your records.

Thanking you,

Yours faithfully,
For Anglo-French Drugs & Industries Ltd.

ANGLO-FRENCH DRUGS & INDUSTRIES LTD. Bangalore-10

Deepa Ramachandran
Company Secretary & Compliance Officer
Encl: a/a

Annexure A

KAMG & ASSOCIATES
Chartered Accountants

192/54, 2nd Floor, Thiruvalluvar Street
East Tambaram, Chennai-600 059.
ganesh@kamg.in,ca_chennai@kamg.in
www.kamg.in

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF ANGLO FRENCH DRUGS & INDUSTRIES LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of **Anglo French Drugs & Industries Limited** ("the Company"), which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate, read with the paragraph below, to provide a basis for our audit opinion on the standalone financial statements.

Due to the COVID - 19 induced restrictions on physical movement and strict timelines, our audit team could not visit the company office regularly at Bengaluru for undertaking the required audit procedures as prescribed under ICAI issued Standards on Auditing and ICAI Advisory for Statutory Audit. Our opinion expressed in the present report is based on the facts, inputs and information made available to us principally through electronic means by the management of the company and also through telephonic interactions and transmission of web enabled text messages with the management for enquiry, clarification and explanation.

Emphasis of Matter

Effects of COVID-19

We draw attention to Note 3(v) of the standalone financial statements, which describes the economic and social consequences/disruption the entity is encountering as a result of COVID-19 which is impacting supply chains, consumer demand and personnel available for work being able to access offices and as the situation with COVID-19 is still evolving the management's assessment of the impact on the subsequent period is dependent on the circumstances as they evolve.

Trade Receivable

We draw attention to Note 11 to the standalone financial statements, on trade receivables from Viva Remedies (an overseas debtor) having outstanding of Rs.1,25,63,657 (USD 240,674) which is more than three years old. The matter relating to realization of the old outstanding balance with Viva Remedies is *sub judice* before Honorable High Court of Karnataka at Bengaluru since 16th December, 2014.

The Company considers the above mentioned receivable is good and realizable and there is no impairment provision has been made in books.

Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon; we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Key audit matter	Principal audit procedures
Physical verification of inventory using alternative audit procedures involving more effort vis-à-vis a non-COVID-19 scenario. Ensuring veracity of inventory balances as on reporting date (Completeness, Accuracy, Cut off and Valuation) adopting alternative audit procedures owing to lock down restrictions and travel restrictions imposed by the Government associated with COVID-19.	Understood the process and tested the management's internal controls to establish the existence of inventory in relation to the process of periodic physical verification carried out by the management, the scope and coverage of the periodic verification programme, the results of such verification including analysis of discrepancies, if any; At selected locations at the end of the year during Mar21 where the management has carried out the physical verification and we have also participated and test checked the quantity and also we corroborate the same with the books of accounts. Inspected, for samples selected, supporting documentation relating to purchases and consumption, and such other third party evidences where applicable.

Trade receivables net of provisions for expected credit loss as in note no. 11 of the standalone financial statement Rs.3620 lakhs. Company determines the allowance for credit losses based on historical loss experience adjusted to reflect current and estimated future economic conditions and has taken into account estimates of possible effect from the pandemic relating to COVID -19.	Our audit procedures related to the allowance for credit losses for trade receivables, based on the documents and correspondence available with the company and by considering subsequent realization of debts after 31.03.2021. We assessed the ageing of trade receivables and advances, the customer's historical payment patterns and whether any post year-end payments has been received up to the date of completing our audit procedures. Further in addition to the above process, a forward-looking expected loss impairment model as prescribed in IND AS 109 "Financial Instruments" was also applied by the Company. This involves judgment as the expected credit losses must reflect information about past events, current conditions and forecasts of future conditions.
Evaluation of uncertain indirect tax positions pertaining to pre-GST regime : The Company has material uncertain service tax and sales tax positions including matters under dispute which involve significant judgment to determine the possible outcome of these disputes.	Reference may please be made to Annexure B to the Independent Auditor's Report wherein the disputed Service Tax, Sales Tax and Value Added Tax and TDS amounting Rs 116 lakhs, Rs 148 lakhs and Rs.18 lakhs respectively have been disclosed. The Service tax dispute (Rs.116 lakhs comprising Rs.81.90 and Rs 34.17 lakhs) is pending with CESTAT and for which Stay Order has been obtained dated 26-11-2010. The status has remained unchanged since that time with no further hearing date is available. During the FY 2019-20 the Company had availed the Subka Viswas Scheme for settlement of the demand of Rs 21.14 lakhs relating to 1.4.2012 till 31.3.2014 and a penalty of equivalent amount aggregating Rs.42 lakhs. The Sales Tax/VAT dispute amounting Rs 148 lakhs is pending with the Joint Commissioner of Commercial Taxes (Appeals) mainly pertaining to non-submission of statutory C Forms, F-forms and is still in appeal stage without any settlement. TDS demand of Rs.18 lakhs which is appearing as default in TRACES, this default is from financial year 2007-08 to 2017-18, This default is due to errors in filling the TDS returns and which are rectifiable by filing revised returns.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance

and Shareholder's Information, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order. As required by Section 143(3) of the Act, based on our audit we report that:

a) We have sought and obtained all the information and explanations read with the second part of 'Basis for Opinion' paragraph, which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

e) On the basis of the written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.

g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended: In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
i. The company has disclosed the impact of pending litigations on its financial position in its standalone financial statements (refer note 40).
ii. The company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.
iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

For **KAMG & ASSOCIATES**
Chartered Accountants
Firm's Registration No.311027E

CA S.Ganesh , Partner
Membership No.232115
Bengaluru dated June 14, 2021
UDIN : 21232115AAAAAE7290

KAMG & Associates

ANNEXURE "A" TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of Anglo French Drugs & Industries Limited of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **ANGLO FRENCH DRUGS & INDUSTRIES LIMITED** ("the Company") as of March 31, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **KAMG & ASSOCIATES**
Chartered Accountants
Firm's Registration No.311027E

KAMG & Associates

CA S.Ganesh , Partner
Membership No.232115
Bengaluru dated June 14, 2021

UDIN: 21232115 AAAAAE7290

ANNEXURE 'B' TO THE INDEPENDENT AUDITOR'S REPORT
(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of Anglo French Drugs & Industries Limited of even date)

i. In respect of the Company's fixed assets:

(a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.

(b) The Company has a program of verification to cover all the items of fixed assets in a phased manner which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Fixed assets were not physically verified by the management during the year.

(c) The title deeds of immovable properties are held in the name of the Company.

ii. As explained to us and on the basis of certificate given to us, the inventory of the Company has been physically verified during the year by the management barring a few locations where physical verification of inventories by the management a date near to the reporting date. Alternative audit procedures were adopted to verify inventory balances for such locations which included reconciliation of last physically verified inventory with the inventory details as on reporting date. In our opinion and according to the information and explanations given to us, the frequency of the verification is reasonable having regard to the size of the Company and the nature of its business.

iii. According to the information and explanations given to us, the Company has not granted loans to companies, firms, limited liability partnerships or other parties as listed in the register maintained under section 189 of the Companies Act, 2013. Accordingly, provisions of the clause 3 (iii) (b) and (c) of the Order are not applicable to the Company.

iv. According to the information and explanations given to us, the Company has not given any loans to directors as mentioned in Section 185 of the Companies Act, 2013 and has not made any investments or given any guarantees and security as mentioned in Section 186 of the Companies Act, 2013. Accordingly, provisions of the clause 3 (iv) of the Order is not applicable to the Company.

v. The Company has not accepted any deposits during the year and so the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Companies Act, 2013 are not applicable.

vi. The Central Government has prescribed for the maintenance of cost records under section 148(1) of the Companies Act, 2013 in respect of the products of the Company and according to the information and explanations given to us such accounts and records have been made and maintained.

vii. According to the information and explanations given to us, in respect of statutory dues:

(a) The Company has generally been regular in depositing with appropriate authorities undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, Sales Tax, Wealth Tax, Service Tax, Excise Duty, Customs Duty, Cess and other material statutory dues applicable to it.

(b) There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, Customs Duty, Cess and other material statutory dues in arrears as at March 31, 2021 for a period of more than six months from the date they became payable.

(c) Details of dues of Service Tax which have not been deposited as at March 31, 2021 on account of dispute are given below:

Nature of dues	Period to which it relates	Amount in lacs	Name of the Assessing Authority
Service tax / Excise	April 2006 to August 2008	82	CESTAT - Bengaluru
Service tax / Excise	Sept 2008 to March 2009	34	CESTAT - Bengaluru
	Total	**116**	
Sales tax / VAT	2002-2003	1	JCCT-Appeals-Patna
Sales tax / VAT	2004-2005	8	JCCT-Appeals-Patna
Sales tax / VAT	2005-2006	3	JCCT-Appeals-Lucknow
Sales tax / VAT	2006-2007	3	JCCT-Appeals-Dhar Pithampur
Sales tax / VAT	2007-2008	2	JCCT-Appeals-Dhar Pithampur
Sales tax / VAT	2008-2009	44	JCCT-Appeals-Dhar Pithampur
Sales tax / VAT	2009-2010	15	JCCT-Appeals-Dhar Pithampur
Sales tax / VAT	2010-2011	15	ACCT-Mumbai and Dhar Pithampur
Sales tax / VAT	2011-2012	55	ACCT- Mumbai
Sales tax / VAT	2014-2015	2	DCCT- Bengaluru
	Total	148	
TDS	2007-08 to 2017-18	18	TDS – CPC

viii. According to the information and explanations given to us, the Company has not defaulted in repayment of loans or borrowings to a financial institution, Bank or Government. The Company has not issued any debentures during the year.

ix. The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) and term loans were applied for the purposes for which those were raised.

x. According to the information and explanations given to us, no fraud on or by the Company has been noticed or reported during the year.

xi. In our opinion and according to the information and explanations given to us, the Company has paid/provided managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.

xii. The Company is not a Nidhi Company and hence reporting under clause 3 (xii) of the Order is not applicable to the Company.

xiii. In our opinion and according to the information and explanations given to us, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

xiv. During the year, the Company has issued fully paid equity shares by way of preferential allotment on a private placement to promoter of the company and section 42 of the Act has been complied with. Refer note 17 of standalone financial statements.

xv. In our opinion and according to the information and explanations given to us, during the year the Company has not entered into any non-cash transactions with its Directors or persons connected to its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

xvi. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

For **KAMG & ASSOCIATES**
Chartered Accountants
Firm's Registration No311027E



CA S. Ganesh, Partner
Membership No.232115
Bengaluru dated June 14, 2021

UDIN: 21232115AAAAAE7290

KAMG & ASSOCIATES
Chartered Accountants

192/54, 2nd Floor, Thiruvalluvar Street
East Tambaram, Chennai-600 059.
ganesh@kamg.in,ca_chennai@kamg.in
www.kamg.in

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF ANGLO FRENCH DRUGS & INDUSTRIES LIMITED

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying consolidated financial statements of **Anglo French Drugs & Industries Limited** ("the Company") and its subsidiary (the Company and its subsidiary together referred to as "the Group"), which comprise the Consolidated Balance Sheet as at March 31, 2021, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows for the year ended on that date, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS") and other accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at March 31, 2021, the consolidated profit, consolidated total comprehensive income, consolidated changes in equity and its consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Group in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate read with the paragraph below and the paragraph (ii) to the paragraph on 'Other Matters', to provide a basis for our audit opinion on the consolidated financial statements.

Due to the COVID - 19 induced restrictions on physical movement and strict timelines, our audit team could not visit the company office regularly at Bengaluru for undertaking the required audit procedures as prescribed under ICAI issued Standards on Auditing and ICAI Advisory for Statutory Audit. Our opinion expressed in the present report is based on the facts, inputs and information made available to us principally through electronic means by the management of the company and also through

telephonic interactions and transmission of web enabled text messages with the management for enquiry, clarification and explanation.

Emphasis of Matter

Effects of COVID-19

We draw attention to Note 3(v) of the consolidated financial statements, which describes the economic and social consequences/disruption the entity is encountering as a result of COVID-19 which is impacting supply chains, consumer demand and personnel available for work being able to access offices and as the situation with COVID-19 is still evolving the management's assessment of the impact on the subsequent period is dependent on the circumstances as they evolve.

Trade Receivable

We draw attention to Note 11 to the consolidated financial statements, on trade receivables from Viva Remedies (an overseas debtor) having outstanding of Rs.1,25,63,657 (USD 240,674) which is more than three years old. The matter relating to realization of the old outstanding balance with Viva Remedies is *sub judice* before Honorable High Court of Karnataka at Bengaluru since 16th December, 2014. The Company considers the above said receivable is good and realizable and there is no impairment provision has been made in books.

Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon; we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Key audit matter	Principal audit procedures
Physical verification of inventory using alternative audit procedures involving more effort vis-à-vis a non-COVID-19 scenario. Ensuring veracity of inventory balances as on reporting date (Completeness, Accuracy, Cut off and Valuation) adopting alternative audit procedures owing to lock down restrictions and travel restrictions imposed by the Government associated with COVID-19.	Understood the process and tested the management's internal controls to establish the existence of inventory in relation to the process of periodic physical verification carried out by the management, the scope and coverage of the periodic verification programme, the results of such verification including analysis of discrepancies, if any; At selected locations at the end of the year during Mar21 where the management has carried out the physical verification and we have also participated and test checked the quantity and also we corroborate the same with the books of accounts. Inspected, for samples selected, supporting documentation relating to purchases and consumption, and such other third party evidences where applicable.

Trade receivables net of provisions for expected credit loss as in note no. 11 of the consolidated financial statement Rs.3667 lakhs. Company determines the allowance for credit losses based on historical loss experience adjusted to reflect current and estimated future economic conditions and has taken into account estimates of possible effect from the pandemic relating to COVID -19.	Our audit procedures related to the allowance for credit losses for trade receivables, based on the documents and correspondence available with the company and by considering subsequent realization of debts after 31.03.2021. We assessed the ageing of trade receivables and advances, the customer's historical payment patterns and whether any post year-end payments has been received up to the date of completing our audit procedures. Further in addition to the above process, a forward-looking expected loss impairment model as prescribed in IND AS 109 "Financial Instruments" was also applied by the Company. This involves judgment as the expected credit losses must reflect information about past events, current conditions and forecasts of future conditions.
Evaluation of uncertain indirect tax positions pertaining to pre-GST regime : The Company has material uncertain service tax and sales tax positions including matters under dispute which involve significant judgment to determine the possible outcome of these disputes.	Reference may please be made to Annexure B to the Independent Auditor's Report wherein the disputed Service Tax, Sales Tax and Value Added Tax and TDS amounting Rs 116 lakhs, Rs 148 lakhs and Rs.18 lakhs respectively have been disclosed. The Service tax dispute (Rs.116 lakhs comprising Rs.81.90 and Rs 34.17 lakhs) is pending with CESTAT and for which Stay Order has been obtained dated 26-11-2010. The status has remained unchanged since that time with no further hearing date is available. During the FY 2019-20 the Company had availed the Subka Viswas Scheme for settlement of the demand of Rs 21.14 lakhs relating to 1.4.2012 till 31.3.2014 and a penalty of equivalent amount aggregating Rs.42 lakhs. The Sales Tax/VAT dispute amounting Rs 148 lakhs is pending with the Joint Commissioner of Commercial Taxes (Appeals) mainly pertaining to non-submission of statutory C Forms, F-forms and is still in appeal stage without any settlement. TDS demand of Rs.18 lakhs which is appearing as default in TRACES, this default is from financial year 2007-08 to 2017-18, This default is due to errors in filling the TDS returns and which are rectifiable by filing revised returns.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Consolidated Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance, consolidated total comprehensive income, consolidated changes in equity and consolidated cash flows of the Group in accordance with the Ind AS and other accounting principles generally accepted in India. The respective Board of Directors of the companies included in the Group are responsible for maintenance of the adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually

or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company and its subsidiary companies which are companies incorporated in India, has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the consolidated financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we

determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

i) We did not audit the financial statements of the subsidiary, whose financial statements reflect total assets of Rs.127 Lacs as at 31st March, 2021, total revenues of Rs.182 Lacs for the period ended on that date, as considered in the consolidated Ind AS financial statements.

ii) The financial statements of the subsidiary are to be audited by other auditor whose report is yet to be furnished to us by the Management. Accordingly our opinion, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the financial statements prepared by the subsidiary which is yet to be audited. We have audited the conversion adjustments made by the Company's management.

Our opinion on the consolidated financial statements and our report on Other Legal and Regulatory Requirements below are formed and prepared in conjunction with the matters as mentioned above.

iii) We draw attention to note 43 in the consolidated financial statements. The subsidiary of the company 'Anglo French Drugs & Industries PTE. Limited Singapore (AFDIPL)' has incurred a net profit of Rs. 42 Lacs during the year ended 31st March, 2021 with an accumulated loss of Rs 18 lakhs as on that date and, as of that date, AFDIPL current assets exceeded its current liabilities by Rs.13 Lacs and its total assets exceeded its total liabilities by Rs.6 Lacs. These factors indicate the existence of a material uncertainty which may cast significant doubt over the AFDIPL`s ability to continue as a going concern. However, there has been improvement in financial performance compared to the preceding financial year and as the ability of the Company to continue as a going concern is primarily dependent on the undertaking of its immediate and ultimate holding company the subsidiary's ability to continue as a going concern is not questioned. Holding Company has to provide continuing financial support to enable the Company to meet its liabilities as and when they fall due.

iv) Trade receivable includes Rs.125.64 Lacs as on 31st March 2021 outstanding for a period of more than three years from Viva Remedies, which is sub judice since 16-12-2014, which in the opinion of the Holding Company is good and recoverable from Viva Remedies.

Separate financial statements of subsidiary which is incorporated outside India have been prepared in accordance with accounting principles generally accepted in that country and which is to be audited by other auditor under generally accepted auditing standards applicable in that country.

We have audited the conversion adjustments made by the Company's management. Our opinion in so far as it relates to the balances and affairs of such subsidiary located outside India is based on the financial statements prepared by the management of the subsidiary which is yet to be signed by the other auditor. The conversion adjustments prepared by the management of the Company and verified by us.

Our opinion is not modified in respect of these matters.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:

a) We have sought and obtained all the information and explanations read with our statements made in the second part of the paragraph on 'Basis for opinion' and paragraph ii) of the 'Other matters' paragraph, which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.

b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books.

c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss including (including Other Comprehensive Income), Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.

d) In our opinion, the aforesaid consolidated financial statements comply with the Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

e) On the basis of the written representations received from the directors of the Company as on March 31, 2021 taken on record by the Board of Directors of the Company and its subsidiaries incorporated in India and the reports of the statutory auditors of its subsidiary companies incorporated in India, none of the directors of the Group companies incorporated in India is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting and the operating effectiveness of such controls; refer to our separate Report in "Annexure A" which is based on the auditor's reports of the Company and its subsidiary companies incorporated in India. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the internal financial control over financial reporting of those companies, for reasons stated therein.

g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:

i. The consolidated financial statements disclose impact of pending litigations on the consolidated financial position of the Group. (Please refer Note 40).

ii. Provision has been made in the consolidated financial statements, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long term contracts including derivative contracts.

iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company and its subsidiary company which is incorporated in India.

For **KAMG & ASSOCIATES**
Chartered Accountants
Firm's Registration No.311027E

CA S. Ganesh, Partner
Membership No.232115
Bengaluru dated June 14, 2021
UDIN : 21232115AAAAAF6861

KAMG & Associates

ANNEXURE "A" TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 1 (f) under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of Anglo French Drugs & Industries Limited of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the consolidated financial statements of the Group as of and for the year ended March 31, 2021, we have audited the internal financial controls over financial reporting of **ANGLO FRENCH DRUGS AND INDUSTRIES LIMITED** (hereinafter referred to as "Company") except the subsidiary company, **ANGLO FRENCH DRUGS & INDUSTRIES PTE LTD** which is not audited by us.

Management's Responsibility for Internal Financial Controls

The Board of Directors of the Company and its subsidiary company, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the respective Companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (" the ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company and its subsidiary companies, which are companies incorporated in India, based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing, prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company and its subsidiary companies, which are companies incorporated in India.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the Company and its subsidiary companies, which are companies incorporated in India, have, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Other Matter

Reporting on Internal Financial Controls over financial reporting is not applicable to subsidiary incorporated outside India.

For **KAMG & ASSOCIATES**
Chartered Accountants
Firm's Registration No.311027E

S C

CA S. Ganesh, Partner
Membership No.232115
Bengaluru dated June 14, 2021

UDIN: 21232115AAAAAF6861

KAMG & Associates

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

REGD. OFF: 41, 3rd CROSS, SSI AREA, V BLOCK, RAJAJINAGAR, BANGALORE - 560 010

CIN: L24230KA1923PLC010205

WEBSITE: www. afdil.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2021

Rupees In Lacs (Except no.of Equity shares and Earnings per share)

PARTICULARS	STANDALONE					CONSOLIDATED	
	3 months ended (31/03/2021) (Audited)	3 months ended (31/12/2020) (Un-Audited)	3 months ended (31/03/2020) (Audited)	Current Year ended (31/03/2021) (Audited)	Previous Year ended (31/03/2020) (Audited)	Current Year ended (31/03/2021) (Audited)	Previous Year ended (31/03/2020) (Audited)
1. Income							
(a) Revenue from operations	3,564	4,096	3,159	15,340	13,013	15,378	13,018
(b) Other Income	5	17	35	89	62	102	155
Total Income	3,569	4,113	3,194	15,429	13,075	15,480	13,173
2. Expenses							
(a) Cost of Material Consumed	343	604	855	3,446	3,213	3,446	3,213
(b) Purchase of Stock in Trade	1,248	1,055	499	3,784	2,595	3,784	2,595
(c) Changes in Inventories of Finished goods, work in progress & Stock in Trade	(45)	293	136	140	69	140	69
(d) Cost of Goods Sold (a+b+c)	1,546	1,952	1,490	7,370	5,877	7,370	5,877
(e) Employee Benefits Expenses	693	737	599	2,722	2,417	2,722	2,417
(f) Finance costs	124	118	145	529	617	529	617
(g) Depreciation and Amortisation Expense	38	69	43	246	254	246	254
(h) Other Expenses	1,059	1,024	792	3,641	3,473	3,650	3,486
Total Expenses (d+e+f+g+h)	3,460	3,900	3,069	14,508	12,638	14,517	12,651
3. Profit(+)/Loss(-) before Exceptional Items (1-2)	109	213	125	921	437	963	522
4. Exceptional items (Net) (Refer note XX)	-	-	-	-	156	-	156
5. Profit(+)/Loss(-) before Tax (3-4)	109	213	125	921	281	963	366
6. Tax Expenses							
i) Current Tax	33	42	29	174	55	174	55
ii) Deferred tax	38	-	-	38	-	38	-
7. Profit(+)/Loss(-) for the period (3-4)	38	171	96	709	226	751	311
8. Other Comprehensive Income							
(i)Items that will not be reclassified to profit & Loss	(14)	(15)	(42)	(33)	(33)	(33)	(33)
(ii)Income tax on items that will not be reclassified to profit or loss	-	4	9	5	9	5	9
Total Other Comprehensive Income	(14)	(11)	(33)	(28)	(24)	(28)	(24)
9. Total Comprehensive Income (5+6)	24	160	63	681	202	723	287
10. Paid up equity share capital (Face value of Rs. 10 each)	129	129	116	129	116	129	116
Reserves excluding revluation reserve				1,473	572	1,478	535
11. Earnings/(Loss) Per Share (Face value of Rs. 10 each)							
a) Basic	3.03	13.28	5.42	58.47	19.47	61.94	26.72
b) Diluted	3.03	13.28	5.42	58.47	19.47	61.94	26.72

NOTES:

1) This statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 amended from time to time.

2) The above Results were taken on record at the meeting of Board of Directors held on 14.06.2021, The results have been reviewed by the Statutory Auditor.

3) The Company has Issued 129000 Equity Shares of face value of 10/-by way of Preferential allotment on Private Placement Basis for an aggregate consideration not exceeding 2,32,20,000/- in accordance with provisions of Section 62(1)(c) read with Section 42 and all other applicable provisions, of the Companies Act, 2013 & and in accordance with the provisions on preferential issue as contained in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The Equity Shares under Preferential Allotment shall rank pari passu in all respects with the existing Equity Shares of the Company.

4) The Board of Directors of the Company have proposed to pay a dividend at Rs. 1.50 per Equity Share (face value of Rs. 10 per Equity Share) at their meeting held on 14.06.2021

5) The Company has no reportable segments other than Pharmaceuticals division as per Ind AS.

6) The figures in respect of previous period have been regrouped/recast wherever necessary.

CA S.Ganesh , Partner
Membership No.232115

KAMG & Associates

ANGLO-FRENCH DRUGS & INDUSTRIES LTD

ABHAY KANORIA

CHAIRMAN & MANAGING DIRECTOR

ANGLO FRENCH DRUGS & INDUSTRIES LTD. Bangalore-10

PLACE: BENGALURU
DATE: 14-06-2021

ANGLO FRENCH DRUGS & INDUSTRIES LTD
STATEMENTS OF ASSETS & LIABILITIES

(Rupees in Lacs)

Particulars	STANDALONE		CONSOLIDATED	
	As at March 31, 2021	As at March 31, 2020	As at March 31, 2021	As at March 31, 2020
ASSETS				
NON-CURRENT ASSETS				
PROPERTY, PLANT AND EQUIPMENT	1,285	1,357	1,285	1,357
Right of Use Assets	73	170	73	170
INTANGIBLE ASSETS	3	4	3	4
FINANCIAL ASSETS				
(i) Investments	8	5	8	5
(ii) Trade Receivables	-	-	-	-
(iii) Other Non-Current Financial Assets	39	112	39	112
DEFERRED TAX ASSETS	-	-		
OTHER NON CURRENT ASSETS	9	7	9	7
TOTAL NON-CURRENT ASSETS	**1,417**	**1,655**	**1,417**	**1,655**
CURRENT ASSETS				
INVENTORIES	3,667	4,279	3,667	4,279
FINANCIAL ASSETS				
(i) Trade Receivables	3,620	2,594	3,626	2,581
(ii) Cash and Cash Equivalents	44	22	64	23
(iii) Other Bank Balances	58	41	58	41
(iv) Other Current Financial Assets	184	91	184	91
CURRENT TAX ASSET (NET)	-	41	-	41
OTHER CURRENT ASSETS	467	602	461	596
TOTAL CURRENT ASSETS	**8,040**	**7,670**	**8,060**	**7,653**
TOTAL ASSETS	**9,457**	**9,325**	**9,477**	**9,308**
EQUITY AND LIABILITIES				
EQUITY				
EQUITY SHARE CAPITAL	129	116	129	116
OTHER EQUITY	1,473	572	1,478	535
TOTAL EQUITY	**1,602**	**688**	**1,607**	**651**
LIABILITIES				
NON-CURRENT LIABILITIES				
FINANCIAL LIABILITIES				
(i) Borrowings	1,647	927	1,647	927
(ii) Other Non-Current Financial Liabilities	311	311	311	311
EMPLOYEE BENEFIT OBLIGATIONS	106	115	106	115
DEFERRED TAX LIABILITIES - NET	38	-	38	-
TOTAL NON-CURRENT LIABILITIES	**2,102**	**1,353**	**2,102**	**1,353**
CURRENT LIABILITIES				
FINANCIAL LIABILITIES				
(i) Borrowings	2,324	3,073	2,324	3,073
(ii) Trade Payables				
(a) Total outstanding dues of MSME .	135	33	135	33
(b) Total outstanding dues other than MSME.	2,111	2,817	2,121	2,832
(iii) Other Current Financial Liabilities	248	627	248	627
Current Tax Liabilities (Net)	34	-	34	-
OTHER CURRENT LIABILITIES	843	688	848	693
EMPLOYEE BENEFIT OBLIGATIONS	58	46	58	46
TOTAL CURRENT LIABILITIES	**5,753**	**7,284**	**5,768**	**7,304**
TOTAL EQUITY AND LIABILITIES	**9,457**	**9,325**	**9,477**	**9,308**

ANGLO-FRENCH DRUGS & INDUSTRIES LTD. Bangalore-10

(S.Ganesh, Partner, ICAI Membership No.232115)

KAMG & Associates

Anglo-French Drugs & Industries Ltd

ASHAY KANORIA
Chairman & Managing Director

ANGLO FRENCH DRUGS & INDUSTRIES LTD (STANDALONE)

Statement of cash flows for the year ended March 31, 2021

(Rupees in lakhs)

Particulars	Year ended March 31, 2021	Year ended March 31, 2020
Cash flow from operating activities		
Profit before income tax	921	281
Adjustments for		
Depreciation and amortisation expense	246	254
Provisions Written Back	(65)	(5)
Interest income classified as investing cash flows	(9)	(7)
Finance costs	529	617
Change in operating assets and liabilities		
(Increase)/Decrease in trade receivables	(1,026)	481
(Increase)/Decrease in inventories	613	(296)
(Increase)/ Decrease in other financial assets	(20)	(18)
(Increase)/Decrease in other non-current assets	(2)	20
(Increase)/Decrease in other current assets	135	(38)
Increase/(Decrease) in trade payables	(536)	305
Increase/ (Decrease) in employee benefit obligations	(32)	(14)
Increase/(Decrease) in other financial liabilities	(378)	(274)
Increase/(Decrease) in other current liabilities	160	263
Cash generated from operations	**535**	**1,570**
Income taxes paid (net of refund)	(99)	(57)
Net cash inflow from operating activities	**436**	**1,513**
Cash flows from investing activities		
Payments for property, plant and equipment	(77)	(308)
Proceeds from sale of property, plant and equipment	3	2
Changes in Other bank balances	(16)	24
Interest received	9	7
Net cash outflow from investing activities	**(81)**	**(275)**
Cash flows from financing activities		
Proceeds from Issuing share capital	232	
Proceeds from borrowings:		
Term Loan	(44)	201
Cash Credit (net)	727	(579)
Others	(727)	(145)
Repayment of borrowings:		
Term Loan	7	(80)
Car Loan	2	(17)
Interest paid	(529)	(617)
Dividends paid	(1)	(1)
Net cash inflow (outflow) from financing activities	**(332)**	**(1,239)**
Net increase (decrease) in cash and cash equivalents	**23**	**0**
Cash and cash equivalents at the beginning of the year	21	21
Cash and cash equivalents at the end of the year	**44**	**21**

For and on behalf of the Board of Directors of
Anglo French Drugs & Industries Limited

S. Ganesh
Partner
Membership Number 232115

Abhay Kanoria
Chairman & MD
DIN : 00108894

KAMG & Associates

ANGLO FRENCH DRUGS & INDUSTRIES LTD. Bangalore-10

ANGLO FRENCH DRUGS & INDUSTRIES LTD (CONSOLIDATED)

Statement of cash flows for the year ended March 31, 2021

(Rupees in lakhs)

	Year ended March 31, 2021	Year ended March 31, 2020
Cash flow from operating activities		
Profit / (Loss) before income tax	**963**	311
Adjustments for		
Depreciation and amortisation expense	246	254
(Gain)/loss on disposal of property, plant and equipment	0	0
Provisions Written Back	(77)	(98)
Interest income classified as investing cash flows	(9)	(7)
Finance costs	529	617
Change in operating assets and liabilities		
(Increase)/Decrease in trade receivables	(1,045)	369
(Increase)/Decrease in inventories	613	(298)
(Increase)/ Decrease in other financial assets	(20)	(17)
(Increase)/Decrease in other non-current assets	(2)	20
(Increase)/Decrease in other current assets	136	(71)
Increase/(Decrease) in trade payables	(531)	399
Increase/ (Decrease) in employee benefit obligations	(32)	(14)
Increase/(Decrease) in other financial liabilities	(379)	(254)
Increase/(Decrease) in other current liabilities	160	308
Cash generated from operations	**551**	**1,513**
Income taxes paid (net of refund)	(99)	1
Net cash inflow from operating activities	**452**	**1,514**
Cash flows from investing activities		
Payments for property, plant and equipment	(75)	(307)
Proceeds from sale of property, plant and equipment	3	2
Changes in Other bank balances	(17)	24
Interest received	9	7
Net cash outflow from investing activities	**(79)**	**(274)**
Cash flows from financing activities		
Proceeds from Issuing share capital	232	
Proceeds from borrowings:		
Term Loan	(43)	200
Cash Credit (net)	727	(579)
Others	(727)	(145)
Repayment of borrowings:		
Term Loan	7	(80)
Car Loan	2	(17)
Interest paid	(529)	(617)
Unclaimed Dividends paid	(1)	(1)
Net cash inflow (outflow) from financing activities	**(331)**	**(1,239)**
Net increase (decrease) in cash and cash equivalents	**42**	**1**
Cash and cash equivalents at the beginning of the year	23	22
Cash and cash equivalents at the end of the year	**65**	**23**

For and on behalf of the Board of Directors of
Anglo French Drugs & Industries Limited

Abhay Kanoria
Chairman & MD
DIN : 00108894

ANGLO FRENCH DRUGS & INDUSTRIES LTD. Bangalore-10

S. Ganesh
Partner
Membership Number 232115

KAMG & Associates

Annexure B

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

14th June, 2021

To,
Listing Compliance Department
Metropolitan Stock Exchange of India Ltd.
Vibgyor Towers, 4th Floor, Plot No. C-62,
G-Block, Opposite Trident Hotel,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400098

Dear Sir/Madam,

Sub: Declaration regarding Audit reports with unmodified opinion for the Audited Standalone and Consolidated Financial Results

It is hereby declared that the Statutory Auditors M/s KAMG & Associates, Chartered Accountants – Statutory Auditors (Firm Registration No.: 311027E) have issued Audit Reports for the Annual Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended 31st March, 2021 with unmodified opinion.

This declaration is issued pursuant to Regulation 33 (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. CIR/CFD/CMD/56/2016 dated 27th May, 2016.

Kindly take the same onto your records.

Thanking you,

Yours faithfully,
For Anglo-French Drugs & Industries Ltd.

ANGLO-FRENCH DRUGS & INDUSTRIES LTD. Bangalore-10

Abhay Kanoria
Chairman & Managing Director
DIN: 00108894

Encl: a/a

ANNEXURE C

1. Mr. Sanat Shirali (DIN: 05260386)		
Sr. No.	**Details of events that needs to be provided**	**Information of such events**
a.	Reason for change viz. ~~appointment, resignation, removal, death or~~ otherwise	Change in designation of Mr. Sanat Shirali (DIN: 05260386) from Non-Executive Director to Independent Director on Board of the Company.
b.	Date of appointment/cessation (as applicable) & terms of appointment	Date of change in designation: 14th June, 2021
c.	Brief profile (in case of appointment)	Mr. Sanat Shirali has a dynamic career of over 4 decades in the Pharma industry. He has been highly successful in driving large scale revenue and profit gains as well as improving on organisational productivity and performance. He is well organised with a track record that demonstrates self-motivation, entrepreneurial ability, creativity, and initiative to achieve corporate goals.
d.	Disclosure of relationships between Directors (in case of appointment of a Director)	Mr. Sanat Shirali is not related to any Director on the Board of the Company.

2. Mrs. Girija Subramanian (DIN: 09196957)		
Sr. No.	**Details of events that needs to be provided**	**Information of such events**
a.	Reason for change viz. appointment, ~~resignation, removal, death or otherwise~~	Appointment of Mrs. Girija Subramanian (DIN: 09196957) as Nominee Director of the Company.
b.	Date of appointment/~~cessation~~ (as applicable) & terms of appointment	Date of appointment: 14th June, 2021
c.	Brief profile (in case of appointment)	Mrs. Girija Subramanian is a Fellow of the Insurance Institute of India and an Associate of the Chartered Insurance Institute, London. Mrs. Girija has over 3 decades of experience in various reinsurance departments, primarily in Aviation, Life, Health and Property classes. Ms. Girija Subramanian is presently the General Manager at General Insurance Corporation of India (GIC) and handles the Claims Vertical which takes care of all non-life claims across all classes of business.
d.	Disclosure of relationships between Directors (in case of appointment of a Director)	Mrs. Girija Subramanian is not related to any Director on the Board of the Company.

ANGLO-FRENCH DRUGS & INDUSTRIES LTD. Bangalore-10

ANNEXURE D

In respect of appointment of M/s Rao, Murthy & Associates, Cost Accountants as Cost Auditors of the Company		
Sr. No.	**Details of events that needs to be provided**	**Information of such events**
a.	Reason for change viz. appointment~~, resignation, removal, death or otherwise~~	Appointment of Rao, Murthy & Associates as Cost Auditors of the Company for cost audit of formulations for FY 2021-22
b.	Date of appointment~~/cessation~~ (as applicable) & terms of appointment	14th June, 2021
c.	Brief profile (in case of appointment)	M/s Rao, Murthy & Associates is a Cost Accounting Firm registered with Institute of Cost Accountants of India (ICAI). The firm is engaged in providing services in areas of Cost Accounting, Cost Audit, Management Audit, Consultancy & Certification,
d.	Disclosure of relationships between Directors (in case of appointment of a Director)	NA.

In respect of appointment of M/s Swaroop Suri & Associates, Practising Company Secretaries as the Secretarial Auditors of the Company		
Sr. No.	**Details of events that needs to be provided**	**Information of such events**
a.	Reason for change viz. appointment~~, resignation, removal, death or otherwise~~	Appointment of Swaroop Suri & Associates, Practising Company Secretaries as Secretarial Auditors of the Company for audit of secretarial records for FY 2021-22
b.	Date of appointment~~/cessation~~ (as applicable) & terms of appointment	14th June, 2021
c.	Brief profile (in case of appointment)	M/s Swaroop Suri & Associates is a firm of practicing Company Secretaries having specialized in providing quality services relating to various Corporate Laws Matters, Audit and Assurance, Governance Advisory and Compliance Checks. The firm is engaged in rendering Company Secretarial and compliance services for Listed, Unlisted Public Companies and Private Companies.
d.	Disclosure of relationships between Directors (in case of appointment of a Director)	NA.

ANGLO-FRENCH DRUGS & INDUSTRIES LTD. Bangalore-10